Q3 Earnings Estimate for Scienture Issued By Maxim Group

Scienture Holdings, Inc. (NASDAQ:SCNX) – Analysts at Maxim Group issued their Q3 2026 EPS estimates for Scienture in a research note issued to investors on Tuesday, September 29th. Maxim Group analyst N. Rahman expects that the company will post earnings of ($1.50) per share for the quarter. The consensus estimate for Scienture’s current full-year earnings is ($5.75) per share. Maxim Group also issued estimates for Scienture’s Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($5.75) EPS and FY2027 earnings at $0.00 EPS.

Several other equities analysts have also weighed in on the company. Zacks Research upgraded Scienture to a “hold” rating in a report on Friday, October 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Scienture in a research note on Monday, September 21st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $37.50.

Scienture Trading Up 1.3%

Shares of NASDAQ:SCNX opened at $3.76 on Monday. The stock has a market capitalization of $6.17 million, a PE ratio of -0.07 and a beta of 3.34. Scienture has a 1 year low of $3.23 and a 1 year high of $65.00. The firm has a fifty day moving average price of $8.87 and a 200 day moving average price of $9.29. The company has a current ratio of 3.04, a quick ratio of 2.97 and a debt-to-equity ratio of 0.15.

Scienture (NASDAQ:SCNX) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.25) by $0.50. The business had revenue of $0.34 million for the quarter, compared to the consensus estimate of $1.96 million.

Institutional Trading of Scienture

An institutional investor recently bought a new stake in Scienture stock. Susquehanna International Group LLP bought a new stake in Scienture Holdings, Inc. (NASDAQ:SCNX) during the second quarter, according to its most recent filing with the SEC. The firm bought 235,117 shares of the company’s stock, valued at approximately $82,000. Susquehanna International Group LLP owned about 0.57% of Scienture at the end of the most recent quarter. 5.68% of the stock is currently owned by institutional investors.

About Scienture

Scienture Holdings, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system and other underserved medical conditions. The company’s strategy centers on differentiated medicines designed to address unmet patient and caregiver needs, including alternative formulations and delivery options.

Scienture’s lead product is ONYDA XR (clonidine hydrochloride) extended-release oral suspension, a non-stimulant prescription treatment for attention-deficit/hyperactivity disorder (ADHD).